What does Advagene Biopharma Co., Ltd. do?

Advagene Biopharma Co., Ltd. (6709.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6709.TWO's market cap?

Advagene Biopharma Co., Ltd. (6709.TWO) has a market capitalization of approximately $1.77 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6709.TWO pay a dividend?

No — Advagene Biopharma Co., Ltd. (6709.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6709.TWO profitable?

Advagene Biopharma Co., Ltd. (6709.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6709.TWO

Advagene Biopharma Co., Ltd.

TWO·Biotechnology · Healthcare

NT$25.85NT$0.35+1.37%

Market capNT$1.77B·Market closed·Aug 26 5:26 AM UTC

Price Chart

NT$25.85+NT$0.35 (+1.37%)today

−57.10%CAGR −15.57%

Select date range

FromTo

Nov 29, 2018Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

6709.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$0.00

Net Income−NT$91.05M

Net Margin—

Operating Cash Flow−NT$87.86M

Capital ExpendituresNT$2.71M

Free Cash Flow−NT$90.56M

Return on Equity−25.5%

Return on Invested Capital−15.7%

Net CashNT$321.45M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6709.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6709.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6709.TWO and 80,000+ other tickers.

About Advagene Biopharma Co., Ltd.

Based in Taipei, Taiwan, Advagene Biopharma Co., Ltd. is a firm dedicated to pioneering advancements in vaccine science and associated medical solutions. Its current development portfolio comprises a nasal spray vaccine for influenza, various allergy-specific vaccines, and an immunotherapy targeting COVID-19.

CEO: Yu-Shen Hsu
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 16
Website: www.advagene.com.tw

Peers

Peers Tab

1762.TW

Chunghwa Chemical Synthesis & Biotech Co., Ltd.

Cap

NT$2.8B

4195.TWO

Genomics BioSci & Tech. Co.,Ltd.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6709.TWO

What does Advagene Biopharma Co., Ltd. do?: Advagene Biopharma Co., Ltd. (6709.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6709.TWO's market cap?: Advagene Biopharma Co., Ltd. (6709.TWO) has a market capitalization of approximately $1.77 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6709.TWO pay a dividend?: No — Advagene Biopharma Co., Ltd. (6709.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6709.TWO profitable?: Advagene Biopharma Co., Ltd. (6709.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.